

Michael R Gold

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4587699/publications.pdf>

Version: 2024-02-01

181
papers

10,064
citations

53660

45
h-index

37111

96
g-index

183
all docs

183
docs citations

183
times ranked

6402
citing authors

#	ARTICLE	IF	CITATIONS
1	Epicardial mapping and ablation of ventricular tachycardia from the coronary venous system in post-coronary bypass patients. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2023, 66, 145-151.	0.6	7
2	European Society of Cardiology Quality Indicators for the care and outcomes of cardiac pacing: developed by the Working Group for Cardiac Pacing Quality Indicators in collaboration with the European Heart Rhythm Association of the European Society of Cardiology. <i>Europace</i> , 2022, 24, 165-172.	0.7	20
3	Is left bundle area pacing the future of pacing for bradycardia?. <i>Heart Rhythm</i> , 2022, 19, 12.	0.3	0
4	CRT Efficacy in "Mid-Range" QRS Duration Among Asians Contrasted to Non-Asians, and Influence of Height. <i>JACC: Clinical Electrophysiology</i> , 2022, 8, 211-221.	1.3	6
5	Temporal Association of Atrial Fibrillation With Cardiac Implanted Electronic Device Detected Heart Failure Status. <i>JACC: Clinical Electrophysiology</i> , 2022, 8, 182-193.	1.3	4
6	Research Opportunities in Autonomic Neural Mechanisms of Cardiopulmonary Regulation. <i>JACC Basic To Translational Science</i> , 2022, 7, 265-293.	1.9	17
7	Estimated incidence of previously undetected atrial fibrillation on a 14-day continuous electrocardiographic monitor and associated risk of stroke. <i>Europace</i> , 2022, .	0.7	13
8	Can We Treat an Older Patient With a New Trick?. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1060-1062.	1.2	0
9	Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial. <i>Circulation</i> , 2021, 143, 7-17.	1.6	132
10	Meta-analysis comparing outcomes of catheter ablation for ventricular arrhythmia in ischemic versus nonischemic cardiomyopathy. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2021, 44, 54-62.	0.5	8
11	Predicting complete heart block after alcohol septal ablation for hypertrophic cardiomyopathy using a risk stratification model and clinical tool. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 393-400.	0.7	6
12	Outcomes of two versus three incision techniques: Results from the subcutaneous ICD post-approval study. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 792-801.	0.8	7
13	Racial difference in atrial size and extracellular matrix homeostatic response to hypertension: Is this a potential mechanism of reduced atrial fibrillation in African Americans?. <i>Heart Rhythm O2</i> , 2021, 2, 37-45.	0.6	5
14	Acute Hemodynamic Effects of Cardiac Resynchronization Therapy Versus Alternative Pacing Strategies in Patients With Left Ventricular Assist Devices. <i>Journal of the American Heart Association</i> , 2021, 10, e018127.	1.6	7
15	Impact of age on catheter ablation of premature ventricular contractions. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 1077-1084.	0.8	2
16	The problematic lag between FDA approval of medical devices and CMS coverage. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 1801-1802.	0.8	2
17	Modified design of stimulation of the left ventricular endocardium for cardiac resynchronization therapy in nonresponders, previously untreatable and high-risk upgrade patients (SOLVE-CRT) trial. <i>American Heart Journal</i> , 2021, 235, 158-162.	1.2	9
18	Device-Detected Atrial Fibrillation Before and After Hospitalisation for Noncardiac Surgery or Medical Illness: Insights From ASSERT. <i>Canadian Journal of Cardiology</i> , 2021, 37, 803-809.	0.8	6

#	ARTICLE	IF	CITATIONS
19	Relationship of paced left bundle branch pacing morphology with anatomic location and physiological outcomes. <i>Heart Rhythm</i> , 2021, 18, 946-953.	0.3	21
20	The Subcutaneous ICD: A Review of the UNTOUCHED and PRAETORIAN Trials. <i>Arrhythmia and Electrophysiology Review</i> , 2021, 10, 108-112.	1.3	14
21	Redefining the Classifications of Response to Cardiac Resynchronization Therapy. <i>JACC: Clinical Electrophysiology</i> , 2021, 7, 871-880.	1.3	33
22	Electrical delays in quadripolar leads with cardiac resynchronization therapy. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 2498-2503.	0.8	4
23	The cost of non-response to cardiac resynchronization therapy: characterizing heart failure events following cardiac resynchronization therapy. <i>Europace</i> , 2021, 23, 1586-1595.	0.7	10
24	Contrast-enhanced image-guided lead deployment for left bundle branch pacing. <i>Heart Rhythm</i> , 2021, 18, 1318-1325.	0.3	29
25	Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trial. <i>Circulation</i> , 2021, 144, 1543-1552.	1.6	190
26	Evaluating outcomes of same-day discharge after catheter ablation for atrial fibrillation in a real-world cohort. <i>Heart Rhythm O2</i> , 2021, 2, 333-340.	0.6	5
27	Same-day discharge after catheter ablation in patients with atrial fibrillation in a large nationwide administrative claims database. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 2432-2440.	0.8	10
28	Estimating Left Ventricular Electrical Delay From the Right Ventricular Lead Electrogram. <i>JACC: Clinical Electrophysiology</i> , 2021, 7, 1195-1196.	1.3	0
29	The Importance of Early Evaluation after Cardiac Resynchronization Therapy to Redefine Response: Pooled Individual Patient Analysis from Five Prospective Studies. <i>Heart Rhythm</i> , 2021, , .	0.3	13
30	A Comparison of the Electrophysiological and Anatomic Characteristics of Pacing Different Branches of the Left Bundle Conduction System. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 781845.	1.1	4
31	Plasticity of left ventricular function with cardiac resynchronization therapy. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2020, 57, 289-294.	0.6	1
32	Editorial commentary: The subcutaneous ICD: An expanding niche or the future of implantable defibrillators?. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 385-386.	2.3	0
33	Comparison of measures of ventricular delay on cardiac resynchronization therapy response. <i>Heart Rhythm</i> , 2020, 17, 615-620.	0.3	23
34	Real-world outcomes of ventricular tachycardia catheter ablation with versus without intracardiac echocardiography. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 417-422.	0.8	16
35	Relationship of Shock Energy to Impedance During Subcutaneous Implantable Cardioverter-Defibrillator Testing. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008631.	2.1	4
36	Healthcare utilization and cost in patients with atrial fibrillation and heart failure undergoing catheter ablation. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 3166-3175.	0.8	8

#	ARTICLE	IF	CITATIONS
37	1-Year Prospective Evaluation of Clinical Outcomes and Shocks. JACC: Clinical Electrophysiology, 2020, 6, 1537-1550.	1.3	24
38	Economic implications of adding a novel algorithm to optimize cardiac resynchronization therapy: rationale and design of economic analysis for the AdaptResponse trial. Journal of Medical Economics, 2020, 23, 1401-1408.	1.0	1
39	The role of electrophysiologic study in high-risk patients with new-onset conduction disturbances following alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2020, 31, 2522-2525.	0.8	0
40	Bilateral Bundle Branch Area Pacing to Achieve Physiological Conduction System Activation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008267.	2.1	25
41	Active-Fixation Atrial Leads and the Risk of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008655.	2.1	1
42	Comparison of Left Bundle Branch and His Bundle Pacing in Bradycardia Patients. JACC: Clinical Electrophysiology, 2020, 6, 1291-1299.	1.3	64
43	Differences in clinical characteristics and reported quality of life of men and women undergoing cardiac resynchronization therapy. ESC Heart Failure, 2020, 7, 2972-2982.	1.4	9
44	Permanent His Bundle Pacing Implantation Facilitated by Visualization of the Tricuspid Valve Annulus. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008370.	2.1	19
45	Pigment nephropathy associated with percutaneous hemodynamic support during ventricular tachycardia ablation. HeartRhythm Case Reports, 2020, 6, 720-723.	0.2	2
46	Intracardiac echocardiography use and outcomes after catheter ablation of ventricular tachycardia. Journal of Comparative Effectiveness Research, 2020, 9, 375-385.	0.6	5
47	Outcomes of subcutaneous implantable cardioverter-defibrillator in dialysis patients: Results from the S-ICD post-approval study. Heart Rhythm, 2020, 17, 1566-1574.	0.3	9
48	The ECG Belt for CRT response trial: Design and clinical protocol. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 1063-1071.	0.5	7
49	Electromagnetic interference from left ventricular assist devices in patients with subcutaneous implantable cardioverter-defibrillators. Journal of Cardiovascular Electrophysiology, 2020, 31, 1195-1201.	0.8	20
50	Future research prioritization in cardiac resynchronization therapy. American Heart Journal, 2020, 223, 48-58.	1.2	13
51	A novel screening test for inappropriate shocks due to myopotentials from the subcutaneous implantable cardioverter-defibrillator. Heart Rhythm O2, 2020, 1, 27-34.	0.6	2
52	Electrocardiogram in Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 2019, 73, 3100-3101.	1.2	0
53	The effect of posture, exercise, and atrial pacing on atrioventricular conduction in systolic heart failure. Journal of Cardiovascular Electrophysiology, 2019, 30, 2892-2899.	0.8	2
54	Evaluation, Management, and Outcomes of Patients Poorly Responsive to Cardiac Resynchronization Device Therapy. Journal of the American College of Cardiology, 2019, 74, 2588-2603.	1.2	60

#	ARTICLE	IF	CITATIONS
55	Optimization of Cardiac Resynchronization Therapy. JACC: Clinical Electrophysiology, 2019, 5, 1026-1027.	1.3	0
56	Left bundle branch pacing for symptomatic bradycardia: Implant success rate, safety, and pacing characteristics. Heart Rhythm, 2019, 16, 1758-1765.	0.3	154
57	Understanding Outcomes with the EMBLEM S-ICD in Primary Prevention Patients with Low EF Study (UNTOUCHED): Clinical characteristics and perioperative results. Heart Rhythm, 2019, 16, 1636-1644.	0.3	48
58	Design and rationale for the Stimulation Of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy in non-responders and previously untreatable patients (SOLVE-CRT) trial. American Heart Journal, 2019, 217, 13-22.	1.2	23
59	Â. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 1075-1075.	0.5	0
60	Factors Associated With High-Voltage Impedance and Subcutaneous Implantable Defibrillator Ventricular Fibrillation Conversion Success. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e006665.	2.1	33
61	A Substernal Defibrillator LeadÂWithÂPacing Capability. JACC: Clinical Electrophysiology, 2019, 5, 197-198.	1.3	0
62	Prophylactic pulmonary vein isolation during cavotricuspid isthmus ablation for atrial flutter: A metaâ€analysis. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 493-498.	0.5	16
63	Left Bundle Branch Pacing. Journal of the American College of Cardiology, 2019, 74, 3039-3049.	1.2	150
64	Rationale and design for AMPLATZER Amulet Left Atrial Appendage Occluder IDE randomized controlled trial (Amulet IDE Trial). American Heart Journal, 2019, 211, 45-53.	1.2	30
65	Competitive athletes with implantable cardioverterâ€defibrillatorsâ€How to program? Data from the Implantable Cardioverterâ€Defibrillator Sports Registry. Heart Rhythm, 2019, 16, 581-587.	0.3	27
66	Development of a biomarker panel to predict cardiac resynchronization therapy response: Results from the SMART-AV trial. Heart Rhythm, 2019, 16, 743-753.	0.3	11
67	Treatment of Subclinical Atrial Fibrillation. Circulation, 2018, 137, 217-218.	1.6	10
68	Use of antibiotic envelopes to prevent cardiac implantable electronic device infections: A metaâ€analysis. Journal of Cardiovascular Electrophysiology, 2018, 29, 609-615.	0.8	22
69	Computer Modeling. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e006104.	2.1	1
70	The interaction of sex, height, and QRS duration on the effects of cardiac resynchronization therapy on morbidity and mortality: an individualâ€patient data metaâ€analysis. European Journal of Heart Failure, 2018, 20, 780-791.	2.9	81
71	Stroke type and severity in patients with subclinical atrial fibrillation: An analysis from the Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial (ASSERT). American Heart Journal, 2018, 201, 160-163.	1.2	26
72	Effect of Interventricular Electrical Delay on Atrioventricular Optimization for Cardiac Resynchronization Therapy. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e006055.	2.1	18

#	ARTICLE	IF	CITATIONS
73	Complex Left Atrial Appendage Morphology Is an Independent Risk Factor for Cryptogenic Ischemic Stroke. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 131.	1.1	6
74	Anesthesia for subcutaneous implantable cardioverter-defibrillator implantation: Perspectives from the clinical experience of a U.S. panel of physicians. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2018, 41, 807-816.	0.5	35
75	The rationale and design of the SMART CRT trial. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2018, 41, 1212-1216.	0.5	6
76	Response by Gold to Letter Regarding Article, "Treatment of Subclinical Atrial Fibrillation: Does One Plus One Always Equal Two?" <i>Circulation</i> , 2018, 138, 124-124.	1.6	1
77	Acute biventricular hemodynamic effects of cardiac resynchronization therapy in right bundle branch block. <i>Heart Rhythm</i> , 2018, 15, 1525-1532.	0.3	10
78	Progression of Device-Detected Subclinical Atrial Fibrillation and the Risk of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2603-2611.	1.2	91
79	Predicting cardiac resynchronization therapy outcomes: It is more than just left bundle branch block. <i>Heart Rhythm</i> , 2018, 15, 1673-1674.	0.3	0
80	A Survey of Current Anesthesia Trends for Electrophysiology Procedures. <i>Anesthesia and Analgesia</i> , 2018, 127, 46-53.	1.1	6
81	Performance of the subcutaneous implantable cardioverter-defibrillator in patients with a primary prevention indication with and without a reduced ejection fraction versus patients with a secondary prevention indication. <i>Heart Rhythm</i> , 2017, 14, 367-375.	0.3	30
82	Left Ventricular Architecture, Long-Term Reverse Remodeling, and Clinical Outcome in Mild Heart Failure With Cardiac Resynchronization. <i>JACC: Heart Failure</i> , 2017, 5, 169-178.	1.9	34
83	Subcutaneous implantable cardioverter-defibrillator Post-Approval Study: Clinical characteristics and perioperative results. <i>Heart Rhythm</i> , 2017, 14, 1456-1463.	0.3	137
84	The Role of Atrioventricular and Interventricular Optimization for Cardiac Resynchronization Therapy. <i>Heart Failure Clinics</i> , 2017, 13, 209-223.	1.0	11
85	The Impact of the PR Interval in Patients Receiving Cardiac Resynchronization Therapy. <i>JACC: Clinical Electrophysiology</i> , 2017, 3, 818-826.	1.3	5
86	Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. <i>European Heart Journal</i> , 2017, 38, 1339-1344.	1.0	428
87	Predictors of short-term clinical response to cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , 2017, 19, 1056-1063.	2.9	27
88	ICD Utilization. <i>JACC: Clinical Electrophysiology</i> , 2017, 3, 299-301.	1.3	0
89	The Design of the Understanding Outcomes with the S-ICD in Primary Prevention Patients with Low EF Study (UNTOUCHED). <i>PACE - Pacing and Clinical Electrophysiology</i> , 2017, 40, 1-8.	0.5	22
90	Subcutaneous Versus Transvenous Implantable Defibrillator Therapy. <i>JACC: Clinical Electrophysiology</i> , 2017, 3, 1475-1483.	1.3	91

#	ARTICLE	IF	CITATIONS
91	Treadmill exercise is good for the heart but not to prevent shocks. <i>Heart Rhythm</i> , 2017, 14, 1440-1441.	0.3	1
92	Rationale and design of the AdaptResponse trial: a prospective randomized study of cardiac resynchronization therapy with preferential adaptive left ventricular only pacing. <i>European Journal of Heart Failure</i> , 2017, 19, 950-957.	2.9	33
93	Impact of Renal Function on Survival After Cardiac Resynchronization Therapy. <i>American Journal of Cardiology</i> , 2017, 120, 262-266.	0.7	6
94	The role of interventricular conduction delay to predict clinical response with cardiac resynchronization therapy. <i>Heart Rhythm</i> , 2017, 14, 1748-1755.	0.3	37
95	Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: Are all beta-blockers equivalent?. <i>Heart Rhythm</i> , 2017, 14, e41-e44.	0.3	91
96	Economic Value and Cost-Effectiveness of Cardiac Resynchronization Therapy Among Patients With Mild Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 204-212.	1.9	30
97	Vagus Nerve Stimulation for the Treatment of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 68, 149-158.	1.2	283
98	Impact of magnetic resonance imaging on ventricular tachyarrhythmia sensing: Results of the Evera MRI Study. <i>Heart Rhythm</i> , 2016, 13, 1631-1635.	0.3	7
99	Magnetic Resonance Imaging-Conditional External Cardiac Defibrillator. <i>Circulation: Cardiovascular Imaging</i> , 2016, 9, .	1.3	1
100	Positive Psychotherapy to Improve Autonomic Function and Mood in ICD Patients (PAM-ICD): Rationale and Design of an RCT Currently Underway. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2016, 39, 458-470.	0.5	57
101	The Effect of Chronic Kidney Disease on Mortality with Cardiac Resynchronization Therapy. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2016, 39, 863-869.	0.5	12
102	Image Quality of Cardiac Magnetic Resonance Imaging in Patients With an Implantable Cardioverter Defibrillator System Designed for the Magnetic Resonance Imaging Environment. <i>Circulation: Cardiovascular Imaging</i> , 2016, 9, .	1.3	48
103	Reduced Mortality Associated With Quadripolar Compared to Bipolar Left Ventricular Leads in Cardiac Resynchronization Therapy. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 426-433.	1.3	41
104	Interventricular Electrical Delay Is Predictive of Response to Cardiac Resynchronization Therapy. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 438-447.	1.3	37
105	Safety and Efficacy of the Subcutaneous Implantable Defibrillator. <i>Journal of the American College of Cardiology</i> , 2016, 67, 445-454.	1.2	64
106	Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts. <i>Heart Rhythm</i> , 2016, 13, 1066-1074.	0.3	92
107	Rationale and Design of the Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy Study (LAPTOP-HF). <i>Journal of Cardiac Failure</i> , 2015, 21, 479-488.	0.7	69
108	Effects of Cardiac Resynchronization Therapy on Cardiac Remodeling and Contractile Function: Results From Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE). <i>Journal of the American Heart Association</i> , 2015, 4, e002054.	1.6	23

#	ARTICLE	IF	CITATIONS
109	The effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: Results of the REVERSE study. <i>Heart Rhythm</i> , 2015, 12, 524-530.	0.3	85
110	Preclinical evaluation of implantable cardioverter-defibrillator developed for magnetic resonance imaging use. <i>Heart Rhythm</i> , 2015, 12, 631-638.	0.3	17
111	A New Algorithm to Reduce Inappropriate Therapy in the Sâ€CD System. <i>Journal of Cardiovascular Electrophysiology</i> , 2015, 26, 417-423.	0.8	107
112	Vagal nerve stimulation for heart failure: new pieces to the puzzle?. <i>European Journal of Heart Failure</i> , 2015, 17, 125-127.	2.9	9
113	Response to Letter Regarding Article â€Temporal Relationship Between Subclinical Atrial Fibrillation and Embolic Eventsâ€. <i>Circulation</i> , 2015, 131, e337-8.	1.6	0
114	Full-Body MRI in Patients With an Implantable Cardioverter-Defibrillator. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2581-2588.	1.2	75
115	The Postâ€Myocardial Infarction Pacing Remodeling Prevention Therapy (PRomPT) Trial: Design and Rationale. <i>Journal of Cardiac Failure</i> , 2015, 21, 601-607.	0.7	3
116	Are Leadless Pacemakers a Niche or theâ€Future of Device Therapy?â€. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1505-1508.	1.2	14
117	Expanding the Boundaries of Heart Failure Care with Interventional and Device Therapy. <i>Heart Failure Clinics</i> , 2015, 11, xiii.	1.0	1
118	Clinical experience with subcutaneous implantable cardioverter-defibrillators. <i>Nature Reviews Cardiology</i> , 2015, 12, 398-405.	6.1	14
119	Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1605-1615.	1.2	458
120	Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review. <i>European Heart Journal</i> , 2015, 36, 2780-2789.	1.0	55
121	Novel measure of electrical dyssynchrony predicts response in cardiac resynchronization therapy: Results from the SMART-AV Trial. <i>Heart Rhythm</i> , 2015, 12, 2402-2410.	0.3	39
122	The Role of I-123 Metaiodobenzylguanidine Imaging in Management of Patients With Heart Failure. <i>American Journal of Cardiology</i> , 2015, 116, S1-S9.	0.7	6
123	Biventricular Pacemaker/Defibrillators Versus Biventricular Pacemakers in Patients with Non-ischemic Cardiomyopathy. <i>Cardiac Electrophysiology Clinics</i> , 2015, 7, 455-459.	0.7	2
124	Long-Term Extrapolation of Clinicalâ€Benefits Among Patients Withâ€Mildâ€Heartâ€Failure Receiving Cardiacâ€Resynchronization Therapy. <i>JACC: Heart Failure</i> , 2015, 3, 691-700.	1.9	10
125	The Role of Atrioventricular and Interventricular Optimization for Cardiac Resynchronization Therapy. <i>Cardiac Electrophysiology Clinics</i> , 2015, 7, 765-779.	0.7	3
126	Developments in Cardiac Resynchronisation Therapy. <i>Arrhythmia and Electrophysiology Review</i> , 2015, 04, 122.	1.3	7

#	ARTICLE	IF	CITATIONS
127	HRS/ACC/AHA Expert Consensus Statement on the Use of Implantable Cardioverter-Defibrillator Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials. <i>Circulation</i> , 2014, 130, 94-125.	1.6	102
128	HRS/ACC/AHA Expert Consensus Statement on the Use of Implantable Cardioverter-Defibrillator Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials. <i>Heart Rhythm</i> , 2014, 11, 1270-1303.	0.3	16
129	HRS/ACC/AHA Expert Consensus Statement on the Use of Implantable Cardioverter-Defibrillator Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1143-1177.	1.2	118
130	Temporal Relationship Between Subclinical Atrial Fibrillation and Embolic Events. <i>Circulation</i> , 2014, 129, 2094-2099.	1.6	579
131	The Effect of Left Ventricular Electrical Delay on the Acute Hemodynamic Response with Cardiac Resynchronization Therapy. <i>Journal of Cardiovascular Electrophysiology</i> , 2014, 25, 624-630.	0.8	27
132	Use of a discrimination algorithm to reduce inappropriate shocks with a subcutaneous implantable cardioverter-defibrillator. <i>Heart Rhythm</i> , 2014, 11, 1352-1358.	0.3	86
133	Newer Indications for ICD and CRT. <i>Cardiology Clinics</i> , 2014, 32, 181-190.	0.9	7
134	Update on Cardiac Resynchronisation Therapy for Heart Failure. <i>European Cardiology Review</i> , 2014, 9, 100.	0.7	0
135	The role of AV and VV optimization for CRT. <i>Journal of Arrhythmia</i> , 2013, 29, 153-161.	0.5	29
136	Comparison of Fixed Tilt and Tuned Defibrillation Waveforms: The PROMISE Study. <i>Journal of Cardiovascular Electrophysiology</i> , 2013, 24, 323-327.	0.8	13
137	An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. <i>European Heart Journal</i> , 2013, 34, 3547-3556.	1.0	410
138	The effect of left ventricular electrical delay on AV optimization for cardiac resynchronization therapy. <i>Heart Rhythm</i> , 2013, 10, 988-993.	0.3	38
139	Who Should Receive the Subcutaneous Implanted Defibrillator?. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2013, 6, 1236-1245.	2.1	40
140	Safety and Efficacy of a Totally Subcutaneous Implantable-Cardioverter Defibrillator. <i>Circulation</i> , 2013, 128, 944-953.	1.6	486
141	Implantable Defibrillators Improve Survival in Patients With Mildly Symptomatic Heart Failure Receiving Cardiac Resynchronization Therapy. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2013, 6, 1163-1168.	2.1	51
142	Effect of QRS Duration and Morphology on Cardiac Resynchronization Therapy Outcomes in Mild Heart Failure. <i>Circulation</i> , 2012, 126, 822-829.	1.6	279
143	Sites of left and right ventricular lead implantation and response to cardiac resynchronization therapy observations from the REVERSE trial. <i>European Heart Journal</i> , 2012, 33, 2662-2671.	1.0	152
144	Interactions between a Left Ventricular Assist Device and Implantable Cardioverter-Defibrillator. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2012, 35, e272-3.	0.5	19

#	ARTICLE	IF	CITATIONS
145	2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. <i>Heart Rhythm</i> , 2012, 9, 1524-1576.	0.3	300
146	The Subcutaneous Defibrillator. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2012, 14, 550-557.	0.4	7
147	Prospective comparison of discrimination algorithms to prevent inappropriate ICD therapy: Primary results of the Rhythm ID Going Head to Head Trial. <i>Heart Rhythm</i> , 2012, 9, 370-377.	0.3	55
148	Acute Performance of a Right Ventricular Automatic Pacing Threshold Algorithm for Implantable Defibrillators. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2012, 35, 259-268.	0.5	2
149	Head-to-Head Comparison of Arrhythmia Discrimination Performance of Subcutaneous and Transvenous ICD Arrhythmia Detection Algorithms: The START Study. <i>Journal of Cardiovascular Electrophysiology</i> , 2012, 23, 359-366.	0.8	192
150	Atrial Support Pacing in Heart Failure: Results from the Multicenter PEGASUS CRT Trial. <i>Journal of Cardiovascular Electrophysiology</i> , 2012, 23, 1317-1325.	0.8	39
151	A prospective, randomized comparison of the acute hemodynamic effects of biventricular and left ventricular pacing with cardiac resynchronization therapy. <i>Heart Rhythm</i> , 2011, 8, 685-691.	0.3	19
152	Economic Implications and Cost-effectiveness of Implantable Cardioverter Defibrillator and Cardiac Resynchronization Therapy. <i>Heart Failure Clinics</i> , 2011, 7, 241-250.	1.0	5
153	Temporal stability of defibrillation thresholds with cardiac resynchronization therapy. <i>Heart Rhythm</i> , 2011, 8, 1008-1013.	0.3	3
154	The impact of cardiac resynchronization therapy on the incidence of ventricular arrhythmias in mild heart failure. <i>Heart Rhythm</i> , 2011, 8, 679-684.	0.3	106
155	The relationship between ventricular electrical delay and left ventricular remodelling with cardiac resynchronization therapy. <i>European Heart Journal</i> , 2011, 32, 2516-2524.	1.0	305
156	Cardiac Resynchronization Therapy in Mild Heart Failure: A Review of the REVERSE and MADIT-CRT Trials. <i>Current Cardiology Reports</i> , 2010, 12, 367-373.	1.3	10
157	Primary Results From the SmartDelay Determined AV Optimization: A Comparison to Other AV Delay Methods Used in Cardiac Resynchronization Therapy (SMART-AV) Trial. <i>Circulation</i> , 2010, 122, 2660-2668.	1.6	366
158	Response to Letters Regarding Article, "Role of Microvolt T-Wave Alternans in Assessment of Arrhythmia Vulnerability Among Patients With Heart Failure and Systolic Dysfunction: Primary Results From the T-Wave Alternans Sudden Cardiac Death in Heart Failure Trial Substudy" <i>Circulation</i> , 2009, 120, .	1.6	1
159	Role of cardiac resynchronization therapy in asymptomatic and mildly symptomatic heart failure. <i>Current Heart Failure Reports</i> , 2009, 6, 44-48.	1.3	1
160	Defibrillation Testing at ICD Implantation: Are We Asking the Wrong Question?. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2009, 32, 567-569.	0.5	13
161	Acute Hemodynamic Effects of Atrial Pacing with Cardiac Resynchronization Therapy. <i>Journal of Cardiovascular Electrophysiology</i> , 2009, 20, 894-900.	0.8	24
162	Impact of atrial prevention pacing on atrial fibrillation burden: Primary results of the Study of Atrial Fibrillation Reduction (SAFARI) trial. <i>Heart Rhythm</i> , 2009, 6, 295-301.	0.3	57

#	ARTICLE	IF	CITATIONS
163	Randomized Trial of Cardiac Resynchronization in Mildly Symptomatic Heart Failure Patients and in Asymptomatic Patients With Left Ventricular Dysfunction and Previous Heart Failure Symptoms. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1834-1843.	1.2	1,060
164	Optimization of superior vena cava coil position and usage for transvenous defibrillation. <i>Heart Rhythm</i> , 2008, 5, 394-399.	0.3	34
165	Use of Traditional and Biventricular Implantable Cardiac Devices for Primary and Secondary Prevention of Sudden Death. <i>Cardiology Clinics</i> , 2008, 26, 419-431.	0.9	5
166	Role of Microvolt T-Wave Alternans in Assessment of Arrhythmia Vulnerability Among Patients With Heart Failure and Systolic Dysfunction. <i>Circulation</i> , 2008, 118, 2022-2028.	1.6	174
167	Sudden cardiac death: The role of risk stratification. <i>American Heart Journal</i> , 2007, 153, 25-33.	1.2	31
168	A Prospective Comparison of AV Delay Programming Methods for Hemodynamic Optimization during Cardiac Resynchronization Therapy. <i>Journal of Cardiovascular Electrophysiology</i> , 2007, 18, 490-496.	0.8	99
169	Comparison of Defibrillation Efficacy and Survival Associated With Right Versus Left Pectoral Placement for Implantable Defibrillators. <i>American Journal of Cardiology</i> , 2007, 100, 243-246.	0.7	40
170	Rationale and design of a randomized clinical trial to assess the role of overdrive and triggered prevention pacing therapies in reducing atrial fibrillation: The Study of Atrial Fibrillation Reduction (SAFARI). <i>American Heart Journal</i> , 2006, 152, 231-236.	1.2	10
171	Complications associated with implantable cardioverter defibrillator replacements associated with recalls. <i>Current Cardiology Reports</i> , 2006, 8, 313-313.	1.3	0
172	Catheter ablation for chronic atrial fibrillation. <i>Current Cardiology Reports</i> , 2006, 8, 313-314.	1.3	0
173	Cardiac resynchronization therapy for heart failure. <i>Current Cardiology Reports</i> , 2006, 8, 314-315.	1.3	1
174	Comparison of stimulation sites within left ventricular veins on the acute hemodynamic effects of cardiac resynchronization therapy. <i>Heart Rhythm</i> , 2005, 2, 376-381.	0.3	93
175	Effectiveness of Rapid Atrial Pacing for Termination of Drug Refractory Atrial Fibrillation: Results of a Dual Chamber Implantable Cardioverter Defibrillator Trial. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2003, 7, 341-344.	0.9	2
176	Safety of a Single Successful Conversion of Ventricular Fibrillation Before the Implantation of Cardioverter Defibrillators. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2003, 26, 483-486.	0.5	32
177	T wave alternans for ventricular arrhythmia risk stratification. <i>Current Opinion in Cardiology</i> , 2003, 18, 1-5.	0.8	7
178	Efficacy and Temporal Stability of Reduced Safety Margins for Ventricular Defibrillation. <i>Circulation</i> , 2002, 105, 2043-2048.	1.6	129
179	Lack of Benefit of an Active Pectoral Pulse Generator on Atrial Defibrillation Thresholds. <i>Journal of Cardiovascular Electrophysiology</i> , 2002, 13, 332-335.	0.8	4
180	Advanced Rhythm Discrimination for Implantable Cardioverter Defibrillators Using Electrogram Vector Timing and Correlation. <i>Journal of Cardiovascular Electrophysiology</i> , 2002, 13, 1092-1097.	0.8	60

#	ARTICLE	IF	CITATIONS
181	The Role of Subcutaneous ICDs in the Prevention of Sudden Cardiac Death. US Cardiology Review, 0, 15, .	0.5	0